Organisation paid for research Program year 2025 Source: CMS Open Payments

Rutgers, the State University

Neither a doctor nor a teaching hospital

Research payments

$2,555,365

383 payments

Through program year 2025, Rutgers, the State University is reported as receiving $2,555,365 in research payments, across 383 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $250,959 42
2024 Research $331,081 133
2023 Research $275,978 41
2022 Research $475,174 64
2021 Research $954,886 80
2020 Research $134,425 16
2019 Research $132,861 7

Breakdown

Who paid Research payments · program years 2019–2025
  1. Exelixis Inc. $712,652 78 payments
  2. BeiGene, Ltd. $329,427 63 payments
  3. Daiichi Sankyo Inc. $267,930 16 payments
  4. Merck Sharp & Dohme Corporation $178,200 2 payments
  5. Amgen Inc. $156,408 3 payments
  6. Bausch Health US, LLC $145,139 131 payments
  7. BeiGene Switzerland GmbH $124,061 2 payments
  8. Amicus Therapeutics, Inc. $122,910 18 payments
  9. BeOne Medicines Ltd. $88,011 7 payments
  10. BTG International, Inc. $79,999 2 payments
Studies the money was for Research payments · program years 2019–2025
  1. Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors $290,117 28 payments
  2. A Randomized, Controlled Phase 3 Study of Cabozantinib XL184 in Combination with Atezolizumab versus Sorafenib in Subjects with Advanced Hepatocellular Carcinoma Who Have Not Received Previous Systemic Anticancer Therapy $217,136 17 payments
  3. U3-1402-A-U202 $188,483 12 payments
  4. A Phase 1 Study of TJ011133 Administered Alone or in Combination with Pembrolizumab or Rituximab in Subjects with Relapsed,Refractory Advanced Solid Tumors and Lymphoma $178,200 2 payments
  5. A Pilot Study of Neoadjuvant Talimogene Laherparepvec (TVEC) and Panitumumab in Patients with Locally Advanced Squamous Cell Carcinoma of the Skin (SCCS) $156,408 3 payments
  6. A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Patients With Previously Untreated Chronic Lymphocytic Leukemia $154,857 11 payments
  7. A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis $145,139 131 payments
  8. Phase 1/1b Study Investigating Safety, Tolerability, PK and Antitumor Activity of Anti-TIGIT Monoclonal Antibody BGB-A1217 in Combination With Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients With Advanced Solid Tumors $133,398 30 payments
  9. A Randomized, Controlled Phase 3 Study of Cabozantinib (XL184) in Combination with Atezolizumab versus Sorafenib in Subjects with Advanced Hepatocellular Carcinoma Who Have Not Received Previous Systemic Anticancer Therapy $132,596 18 payments
  10. Phase 1/1b Study Investigating Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of Anti-TIGIT Monoclonal Antibody BGB-A1217 in Combination with Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients with Unresectable Locally Advan $97,890 19 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record